The Application of Botulinum Toxin in the Prostate

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2375-2382

  Chuang, Yao Chi ^a   Chancellor, Michael B ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

botulinum toxins; injections; prostate; urination disorders

Indexed keywords

ACETYLCHOLINE; AMINOGLYCOSIDE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; GENTAMICIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARM WEAKNESS; CLINICAL TRIAL; CYSTOSCOPY; DOG; DRUG EFFECT; DRUG MECHANISM; DYSPHAGIA; EATON LAMBERT SYNDROME; FLOW RATE; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; SENSORY SYSTEM;

ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRALESIONAL; MALE; NEUROMUSCULAR AGENTS; PROSTATE; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 33751059507     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.127     Document Type: Review

References (50)

1. Smith C.P., and Chancellor M.B. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 171 (2004) 2128
2. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39 (2001) 1815
3. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol 139 (1988) 919
4. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164 (2000) 692
5. Shaari C.M., Sanders I., Wu B.L., and Biller H.F. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 112 (1995) 566
6. Doggweiler R., Zermann D.H., Ishigooka M., and Schmidt R.A. Botox-induced prostatic involution. Prostate 37 (1998) 44
7. Lowe P.L., Cerdan-Sanz S., and Lowe N.J. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhydrosis: efficacy and duration with repeated treatments. Dermatol Surg 29 (2003) 545
8. Pennefather J.N., Lau W.A., Mitchelson F., and Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 20 (2000) 193
9. Ventura S., Pennefather J., and Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 94 (2002) 93
10. Maria G., Brisinda G., Civello I.M., Bentivoglio A.R., Sganga G., and Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 (2003) 259
11. Kuo H.C. Prostate botulinum toxin A injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65 (2005) 670
12. Chuang Y.C., Chiang P.H., Huang C.C., Yoshimura N., and Chancellor M.B. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66 (2005) 775
13. Chuang Y.C., Tu C.H., Huang C.C., Lin H.J., Chiang P.H., Yoshimura N., et al. Intraprostatic injection of botulinum toxin type A injection relieves bladder outlet obstruction and induces prostate apoptosis. BMC Urol 6 (2006) 12
14. Chuang Y.C., Huang C.C., Kang H.Y., Chiang P.H., DeMiguel F., Yoshimura N., et al. Novel action of botulinum toxin on the stromal and epithelial components of prostate gland. J Urol 173 (2006) 1158
15. Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J., Benfenati F., et al. Botulinum neurotoxins serotypes A and E cleave Snap-25 at distinct COOH-terminal peptide bonds. FEBS Lett 335 (1993) 99
16. Rohrbach S., Olthoff A., Laskawim R., Gieferm B., and Gotzm W. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 110 (2001) 1045
17. Mackenzie I., Burnstock G., and Dolly J.O. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7 (1982) 997
18. Smith C.P., Franks M.E., McNeil B.K., Ghosh R., de Groat W.C., Chancellor M.B., et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169 (2003) 1896
19. Argoff C.E. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 18 (2002) S177
20. Chuang Y.C., Yoshimura N., Huang C.C., Chiang P.H., and Chancellor M.B. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172 (2004) 1529
21. Khera M., Somogyi G.T., Kiss S., Boone T.B., and Smith C.P. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45 (2004) 987
22. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain 107 (2004) 125
23. Jabbari B., Maher N., and DiFazio M.P. Botulinum toxin a improved burning pain and alloying in two patients with spinal cord pathology. Pain Med 4 (2003) 206
24. 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity. J Urol 174 (2005) 977
25. Scott A.B., and Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3 (1988) 333
26. Wyndaele J.J., and Van Dromme S.A. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40 (2002) 599
27. Kim H.S., Hwang J.H., Jeong S.T., Lee Y.T., Lee P.K., Suh Y.L., et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 45 (2003) 200
28. Santos J.I., Swensen P., and Glasgow L.A. Potentiation of clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 68 (1981) 50
29. Jankovic J., Vuong K.D., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186
30. Lujan M., Paez A., Llanes L., Angulo J., and Berenguer A. Role of autonomic innervation in rat prostatic structure maintenance: a morphometric analysis. J Urol 160 (1998) 1919
31. Coffey D.S., and Walsh P.C. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17 (1990) 461
32. Lin A.T., Chen M.T., Chiang H., Yang C.H., and Chang L.S. Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. J Urol 154 (1995) 1930
33. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169 (2003) 1520
34. Walsh P.C. Treatment of benign prostatic hyperplasia. N Engl J Med 335 (1996) 557
35. Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 81 (1998) 29
36. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol 170 (2003) 530
37. Ravindranath N., Wion D., Brachet P., and Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22 (2001) 432
38. Marinese D., Patel R., and Walden P.D. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54 (2003) 230
39. Guercini F., Giannantoni A., Bard R.L., Brisinda G., Cadeddu F., Maria G., et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia a multicenter feasibility study. J Urol 173 suppl (2005) 376 abstract 1387
40. Larson T.R., Scottsdale A.Z., Huidobro C., and Acevedo C. Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate. J Urol 173 suppl (2005) 376 abstract 1386
41. Park D.S., Cho T.W., Lee Y.K., Lee J.H., Hong Y.K., and Lee Y.T. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia (2005), Presented at annual meeting of International Continence Society, Montreal, Quebec, Canada August 28-September 2
42. Chuang Y.-C., Chiang P.H., Hsien K., Yoshimura N., DeMiguel F., and Chancellor M. Beneficial effects of intraprostatic botulinum toxin type A injection on LUTS and quality of life in BPH patients. J Urol 175 suppl (2006) 464 abstract 1436
43. Plante M.K., Folsom J.B., and Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 172 (2004) 20
44. Chalfin S.A., and Bradley W.E. The etiology of detrusor hyperreflexia in patients with infravesical obstruction. J Urol 127 (1982) 938
45. Pontari M.A., and Ruggieri M.R. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 172 (2004) 839
46. Danuser H., Springer J.P., Katofiasc M.A., and Thor K.B. Extrinsic innervations of the cat prostate gland: a combined tracing and immunohistochemical study. J Urol 157 (1997) 1018
47. Dinis P., Charrua A., Avelino A., Nagy I., Quintas J., Ribau U., et al. The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Eur Urol 48 (2005) 162
48. Chuang Y.-C., Hsien K., DeMiguel F., Huang C.C., Wu M., Chiang P.-H., et al. Intraprostatic capsaicin injection as a novel model for non-bacteria prostatitis. J Urol 175 suppl (2006) 175
49. Nelson W.G., De Marzo A.M., De Weese T.L., and Isaacs W.B. The role of inflammation in the pathogenesis of prostate cancer. J Urol, part 2 172 (2004) S6
50. Chuang Y.C., Giannantoni A., and Chancellor M.B. The potential and promise of using botulinum toxin in the prostate gland. BJU Int 98 (2006) 28